AboutLiverTumors.com Contact Us

Buy Sorafenib (Nexavar) tablets online

Sorafenib (trade names include Nexavar, Sorafenat, Soranib, Soranix) is an anti-cancer drug from protein kinase inhibitors pharmacological group. This medication is used for the treatment of advanced primary liver cancer (hepatocellular carcinoma), primary kidney cancer (advanced renal cell carcinoma, advanced renal cancer), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma. It is in researcj studies for the treatment of lung, brain (recurrent glioblastoma), ovarian cancer, desmoid tumor (aggressive fibromatosis). It works by inhibiting protein kinases enzymes in cancer cells.

How and where to order Sorafenib (Nexavar) 200 mg tablets online:

Prices: from $5.50 per pill
Forms: Sorafenib (Nexavar) 200 mg tablets
Quantity: 30, 60, 90, 120 pills
Type: Nexavar (Sorafenib Tosylate) generic
Payment: Visa, MasterCard, AmEx, E-Check (ACH), JCB, Bitcoin
Delivery: Regular airmail and express courier
Shipping: Worldwide

Related medications:

  • Acalabrutinib (Calquence)
  • Binimetinib (Mektovi)
  • Cediranib (Recentin)
  • Ceritinib (Zykadia)
  • Cobimetinib (Cotellic)
  • Dacomitinib (Vizimpro)
  • Dasatinib (Sprycel)
  • Erlotinib (Tarceva)
  • Gilteritinib (Xospata)
  • Lorlatinib (Lorbrena)
  • Masitinib (Masivet)
  • Osimertinib (Tagrisso)
  • Ruxolitinib (Jakafi)
  • Temsirolimus (Torisel)
  • Trametinib (Mekinist)
  • Vandetanib (Caprelsa)
  • Vemurafenib (Zelboraf)

    Pharmacological and medical categories:

  • Anti cancer drugs
  • Anti tumor medicines
  • Medications for the treatment of liver tumors

    ATC codes:

  • L - Antineoplastic and immunomodulating agents
  • L01 - Antineoplastic agents
  • L01X - Other antineoplastic agents
  • L01XE - Protein kinase inhibitors
  • L01XE05 - Sorafenib

    ICD-10 codes:

  • Malignant neoplasm of liver and intrahepatic bile ducts - C22
  • Liver cell carcinoma - C22.0
  • Malignant neoplasm of bronchus and lung - C34
  • Malignant neoplasm of ovary - C56
  • Malignant neoplasm of kidney, except renal pelvis - C64
  • Malignant neoplasm of brain - C71
  • Malignant neoplasm of thyroid gland - C73
  • Neoplasm of uncertain behavior of other and unspecified sites - D48
  • Fibroblastic disorders - M72

    Pregnancy categories:

  • D - Australia
  • D - United States (Positive evidence of risk)

    Salts and other forms:

  • Sorafenib Base
  • Sorafenib Tosylate

    Synonyms, international and chemical names:

  • Sorafenibi
  • Sorafenibum
  • Sorafeniib

    Brands, generics, trade names:

  • Nexavar - Bayer, Onyx Pharmaceuticals
  • Sorafenat - Natco Pharma
  • Soranib - Cipla
  • Soranix - Beacon Pharmaceuticals

    Indications and usage:

    Nexavar (Sorafenib Tosylate) is a kinase inhibitor indicated for the treatment of:

  • Unresectable hepatocellular carcinoma
  • Advanced renal cell carcinoma
  • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment

    Dosage and administration:

  • 400 mg (2 tablets) orally twice daily without food.
  • Treatment interruption and/or dose reduction may be needed to manage adverse reactions.

    Dosage forms and strengths:

    Nexavar (Sorafenib Tosylate) 200 mg oral tablets


  • Sorafenib is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of Nexavar.
  • This drug in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.

    Warnings and precautions:

  • Cardiovascular Events: Consider temporary or permanent discontinuation of Nexavar.
  • Bleeding: Discontinue Nexavar if needed.
  • Hypertension: Monitor blood pressure weekly during the first 6 weeks and periodically thereafter.
  • Dermatologic Toxicities: Interrupt and/or decrease dose. Discontinue for severe or persistent reactions, or if Stevens-Johnson syndrome and toxic epidermal necrolysis is suspected.
  • Gastrointestinal Perforation: Discontinue Nexavar.
  • QT Prolongation: Monitor electrocardiograms and electrolytes inpatients at increased risk for ventricular arrhythmias.
  • Drug-Induced Liver Injury: Monitor liver function tests regularly; discontinue for unexplained transaminase elevations.
  • Embryo-Fetal Toxicity: Sorafenib may cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.
  • Impairment of TSH suppression in DTC: Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer.

    Adverse reactions, side effects:

    The most common adverse reactions ( >= 20%) for Nexavar tablets are diarrhea, fatigue, infection, alopecia, hand-foot skin reaction, rash, weight loss, decreased appetite, nausea, gastrointestinal and abdominal pains, hypertension, and hemorrhage.

    Drug interactions:

    Avoid strong CYP3A4 inducers.

    Use in specific populations:

  • Lactation: Advise women not to breastfeed.
  • Females and Males of Reproductive Potential: Verify pregnancy status prior to initiation of Nexavar (Sorafenib Tosylate) 200 mg tablets,

    Updated: February 2020
    Reviewed: February 2020